Status:
COMPLETED
Efficacy and Safety of Lornoxicam in Patients With Acute Coronary Syndrome
Lead Sponsor:
Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation
Conditions:
Acute Coronary Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether nonsteroidal antiinflammatory drug lornoxicam in combination with low dose aspirin (100mg/day) is effective and safe in patients with Acute Coronary S...
Detailed Description
Nonsteroidal Antiinflammatory drugs (NSAIDs) are the most frequently prescribed drugs in the world. There are a lot of controversial information published during recent years about NSAID cardiosafety....
Eligibility Criteria
Inclusion
- Unstable angina verified during first 48 hours after admitting to the hospital or
- Acute Miocardial infarction without St-segment elevation verified during first 48 hours after admitting to the hospital
Exclusion
- High risk of bleeding of any location
- Any kind of acute and active inflammatory process (excluding acute coronary syndrome)
- Aspirin or NSAID Intolerability
- No informed consent
- Acute peptic stomach or duodenum ulcer
- Acute or chronic renal failure (serum creatinin \>300 mmol/l)
- Acute cerebrovascular bleeding
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT00997750
Start Date
March 1 2007
End Date
June 1 2009
Last Update
October 19 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Central Clinical Hospital of Presidential Department Of Russian Federation
Moscow, Russia